The role of IL-1 in the pathogenesis of heart disease

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Interleukin (IL)-1 consists of two distinct ligands, IL-1α and IL-1β, with indistinguishable biological activities that signal through the IL-1 type I receptor (IL-1RI). A naturally occurring IL-1 receptor antagonist (IL-1Ra) binds to IL-1RI without initiating signal transduction and prevents IL-1 signaling, competitively inhibiting IL-1-mediated responses. Emerging evidence suggests that the balance between IL-1 agonists and antagonists plays an essential role in a variety of cardiovascular conditions. IL-1 may play a role in atherothrombotic disease by promoting the formation of atheromatous lesions, enhancing vascular inflammation, and triggering plaque destabilization. Following myocardial infarction, IL-1 critically regulates the inflammatory response and is involved in the development of adverse remodeling by enhancing expression of matrix metalloproteinases. IL-1 signaling may also be an essential mediator in the pathogenesis of heart failure by suppressing cardiac contractility, promoting myocardial hypertrophy, and inducing cardiomyocyte apoptosis. The present review summarizes current available data showing the significant role of IL-1 signaling in heart disease and raising the possibility that IL-1 inhibitors (such as anakinra, a nonglycosylated recombinant human IL-1Ra) may be clinically useful agents in patients with certain cardiovascular conditions.

Original languageEnglish (US)
Pages (from-to)165-176
Number of pages12
JournalArchivum Immunologiae et Therapiae Experimentalis
Volume57
Issue number3
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Interleukin-1
Heart Diseases
Interleukins
Interleukin-1 Type I Receptors
Interleukin 1 Receptor Antagonist Protein
Interleukin-1 Receptors
Proxy
Matrix Metalloproteinases
Cardiac Myocytes
Hypertrophy
Blood Vessels
Signal Transduction
Heart Failure
Myocardial Infarction
Apoptosis
Ligands
Inflammation

Keywords

  • Cardiac fibrosis
  • Hypertrophy
  • Inflammation
  • Interleukin-1
  • Myocardial ischemia
  • Remodeling

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The role of IL-1 in the pathogenesis of heart disease. / Bujak, Marcin; Frangogiannis, Nikolaos G.

In: Archivum Immunologiae et Therapiae Experimentalis, Vol. 57, No. 3, 06.2009, p. 165-176.

Research output: Contribution to journalArticle

@article{07ce6a843e434948bb57788d6951f21d,
title = "The role of IL-1 in the pathogenesis of heart disease",
abstract = "Interleukin (IL)-1 consists of two distinct ligands, IL-1α and IL-1β, with indistinguishable biological activities that signal through the IL-1 type I receptor (IL-1RI). A naturally occurring IL-1 receptor antagonist (IL-1Ra) binds to IL-1RI without initiating signal transduction and prevents IL-1 signaling, competitively inhibiting IL-1-mediated responses. Emerging evidence suggests that the balance between IL-1 agonists and antagonists plays an essential role in a variety of cardiovascular conditions. IL-1 may play a role in atherothrombotic disease by promoting the formation of atheromatous lesions, enhancing vascular inflammation, and triggering plaque destabilization. Following myocardial infarction, IL-1 critically regulates the inflammatory response and is involved in the development of adverse remodeling by enhancing expression of matrix metalloproteinases. IL-1 signaling may also be an essential mediator in the pathogenesis of heart failure by suppressing cardiac contractility, promoting myocardial hypertrophy, and inducing cardiomyocyte apoptosis. The present review summarizes current available data showing the significant role of IL-1 signaling in heart disease and raising the possibility that IL-1 inhibitors (such as anakinra, a nonglycosylated recombinant human IL-1Ra) may be clinically useful agents in patients with certain cardiovascular conditions.",
keywords = "Cardiac fibrosis, Hypertrophy, Inflammation, Interleukin-1, Myocardial ischemia, Remodeling",
author = "Marcin Bujak and Frangogiannis, {Nikolaos G.}",
year = "2009",
month = "6",
doi = "10.1007/s00005-009-0024-y",
language = "English (US)",
volume = "57",
pages = "165--176",
journal = "Archivum Immunologiae et Therapiae Experimentalis",
issn = "0004-069X",
publisher = "Birkhauser Verlag Basel",
number = "3",

}

TY - JOUR

T1 - The role of IL-1 in the pathogenesis of heart disease

AU - Bujak, Marcin

AU - Frangogiannis, Nikolaos G.

PY - 2009/6

Y1 - 2009/6

N2 - Interleukin (IL)-1 consists of two distinct ligands, IL-1α and IL-1β, with indistinguishable biological activities that signal through the IL-1 type I receptor (IL-1RI). A naturally occurring IL-1 receptor antagonist (IL-1Ra) binds to IL-1RI without initiating signal transduction and prevents IL-1 signaling, competitively inhibiting IL-1-mediated responses. Emerging evidence suggests that the balance between IL-1 agonists and antagonists plays an essential role in a variety of cardiovascular conditions. IL-1 may play a role in atherothrombotic disease by promoting the formation of atheromatous lesions, enhancing vascular inflammation, and triggering plaque destabilization. Following myocardial infarction, IL-1 critically regulates the inflammatory response and is involved in the development of adverse remodeling by enhancing expression of matrix metalloproteinases. IL-1 signaling may also be an essential mediator in the pathogenesis of heart failure by suppressing cardiac contractility, promoting myocardial hypertrophy, and inducing cardiomyocyte apoptosis. The present review summarizes current available data showing the significant role of IL-1 signaling in heart disease and raising the possibility that IL-1 inhibitors (such as anakinra, a nonglycosylated recombinant human IL-1Ra) may be clinically useful agents in patients with certain cardiovascular conditions.

AB - Interleukin (IL)-1 consists of two distinct ligands, IL-1α and IL-1β, with indistinguishable biological activities that signal through the IL-1 type I receptor (IL-1RI). A naturally occurring IL-1 receptor antagonist (IL-1Ra) binds to IL-1RI without initiating signal transduction and prevents IL-1 signaling, competitively inhibiting IL-1-mediated responses. Emerging evidence suggests that the balance between IL-1 agonists and antagonists plays an essential role in a variety of cardiovascular conditions. IL-1 may play a role in atherothrombotic disease by promoting the formation of atheromatous lesions, enhancing vascular inflammation, and triggering plaque destabilization. Following myocardial infarction, IL-1 critically regulates the inflammatory response and is involved in the development of adverse remodeling by enhancing expression of matrix metalloproteinases. IL-1 signaling may also be an essential mediator in the pathogenesis of heart failure by suppressing cardiac contractility, promoting myocardial hypertrophy, and inducing cardiomyocyte apoptosis. The present review summarizes current available data showing the significant role of IL-1 signaling in heart disease and raising the possibility that IL-1 inhibitors (such as anakinra, a nonglycosylated recombinant human IL-1Ra) may be clinically useful agents in patients with certain cardiovascular conditions.

KW - Cardiac fibrosis

KW - Hypertrophy

KW - Inflammation

KW - Interleukin-1

KW - Myocardial ischemia

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=70349488694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349488694&partnerID=8YFLogxK

U2 - 10.1007/s00005-009-0024-y

DO - 10.1007/s00005-009-0024-y

M3 - Article

C2 - 19479203

AN - SCOPUS:70349488694

VL - 57

SP - 165

EP - 176

JO - Archivum Immunologiae et Therapiae Experimentalis

JF - Archivum Immunologiae et Therapiae Experimentalis

SN - 0004-069X

IS - 3

ER -